Project Grant SB1AA032146
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- This federal Project Grant award of $423,313, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to develop an AI-driven platform for identifying potential therapeutic candidates for Alcohol Use Disorder (AUD). The award to Biosymetrics Inc., based in Huntington, NY, will leverage the company's existing AI-based zebrafish behavioral screening technology and AUD-specific experimental findings to create a commercial...
- This federal Project Grant award of $194,062, provided by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs), supports the development and pilot testing of a digital pill system (DPS) to measure and improve adherence to acamprosate medication in individuals with alcohol-associated liver disease (ALD) and alcohol use disorder (AUD). The key products/services to be delivered under this 5-year grant include: 1) Developing a user-centered adherence...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $999,393 Cooperative Agreement to Stress Therapeutics, Inc., a California-based pharmaceutical company, to conduct Investigational New Drug (IND)-enabling studies for a novel therapeutic to treat Alcohol Use Disorder (AUD). The key products and services to be delivered include: 1) Manufacture and validation of the test article for IND-enabling studies; 2) Development and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $390,454 Project Grant to Envisbio LLC to develop novel therapeutic aptamers targeting phosphodiesterase 4B (PDE4B) for the treatment of alcohol use disorder (AUD). The project aims to identify and characterize PDE4B-specific aptamers that can modulate PDE4B activity, with the goal of advancing these modulators into in vivo testing and eventual human clinical trials for...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,742,166 Project Grant under CFDA 93.273 - Alcohol Research Programs to the Trustees of Boston University, doing business as Boston University Medical Campus. The grant supports a comprehensive evaluation to assess the associations of state alcohol taxation and related policy environment with state-level alcohol treatment facilities capacity and key alcohol use disorder (AUD) health service outcomes. The project...
- This federal Project Grant award of $499,987 was provided by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs) to CFD Research Corporation to develop a High Throughput Alcohol Screening Platform (HT-ASP) incorporating cortical organoids. The goal is to create a complex, in vitro model of the human brain using organoid technology to better understand the effects of alcohol and screen potential therapeutics. This 1-year award, starting on May 15,...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $305,545 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Spark Biomedical Inc. to study the use of transcutaneous auricular neurostimulation (TAN) as a treatment for alcohol use disorder. The research aims to investigate the efficacy of TAN in reducing alcohol withdrawal symptoms and developing neuroimaging biomarkers for alcohol use disorder. Spark Biomedical, a small disadvantaged business...
- This federal Cooperative Agreement award of $1,001,425.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to develop a novel and functionally selective 5-HT2C receptor agonist for treating Alcohol Use Disorder (AUD). The project's goal is to confirm and extend the drug candidacy of KB128, a proprietary compound developed by Kuleon LLC, as a potential therapeutic medication for AUD. The award will...
- This Project Grant award was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which falls under the federal Alcohol Research Programs (CFDA 93.273). The $692,723 award will support a double-blind, placebo-controlled clinical trial to test whether the drug suvorexant can be used as a novel therapeutic for alcohol use disorder (AUD) and stress-related drinking. The 5-year project, running from September 2025 through August 2030, will be conducted by researchers at The...
- This federal Project Grant award of $152,643 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports the development and characterization of a novel positron emission tomography (PET) radioligand, (S)-[18F]OF-NB1, to quantify the availability of GluN2B-containing N-methyl-D-aspartate receptors (GluN2BR) in people with alcohol use disorder (AUD). The two-phase project will first establish the imaging properties and...